Page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Page 10
Page 11
Page 12
Page 13
Page 14
Page 15
Page 16
Page 17
Page 18
Page 19
Page 20
Page 21
Page 22
Page 23
Page 24
Page 25
Page 26
Page 27
Page 28
Page 29
Page 30
Page 31
Page 32
Page 33
Page 34
Page 35
Page 36
Page 37
Page 38
Page 39
Page 40
Page 41
Page 42
Page 43
Page 44
Page 45
Page 46
Page 47
Page 48
Page 49
Page 50
Page 51
Page 52
Page 53
Page 54
Page 55
Page 56
Page 57
Page 58
Page 59
Page 60
Page 61
Page 62
Page 63
Page 64
Page 65
Page 66
Page 67
Page 68
Page 69
Page 70
Page 71
Page 72
Page 73
Page 74
Page 75
Page 76
Page 77
Page 78
Page 79
Page 80
Page 81
Page 82
Page 83
Page 84
Page 85
Page 86
Page 87
Page 88
Page 89
Page 90
Page 91
Page 92
Page 93
Page 94
Page 95
Page 96
Page 97
Page 98
Page 99
Page 100
Page 101
Page 102
Page 103
Page 104
Page 105
Page 106
Page 107
Page 108
Page 109
Page 110
Page 111
Page 112
Page 113
Page 114
Page 115
Page 116
Page 117
Page 118
Page 119
Page 120
Page 121
Page 122
Page 123
Page 124
Page 125
Page 126
Page 127
Page 128
Page 129
Page 130
Page 131
Page 132
Page 133
Page 134
Page 135
Page 136
Page 137
Page 138
Page 139
Page 140
Page 141
Page 142
Page 143
Page 144
Page 145
Page 146
Page 147
Page 148
Page 149
Page 150
Page 151
Page 152
Page 153
Page 154
Page 155
Page 156
Page 157
Page 158
Page 159
Page 160
Page 161
Page 162
Page 163
Page 164
Page 165
Page 166
Page 167
Page 168
Page 169
Page 170
Page 171
Page 172
Page 173
Page 174
Page 175
Page 176
Page 177
Page 178
Page 179
Page 180
Page 181
Page 182
Page 183
Page 184
Page 185
Page 186
Page 187
Page 188
Page 189
Page 190
Page 191
Page 192
Page 193
Page 194
Page 195
Page 196
Page 197
Page 198
Page 199
Page 200
Page 201
Page 202
Page 203
Page 204
Page 205
Page 206
Page 207
Page 208
Page 209
Page 210
Page 211
Page 212
190 In my scientific career to date I have gained considerable experi- ence working in both the UK and worldwide. I have a strong background in the disciplines of immunology and molecular biology within the veterinary virology and parasitology fields. Having studied to be a veterinary surgeon at the Royal Veterinary College in London I then worked as a veterinary practitioner in a mixed private practice in the south of the UK for three years. On leaving private practice I successfully completed an MSc in Tropical Veterinary Science at the Centre for Veterinary Tropical Medicine CTVM at Edinburgh University. During my MSc I had my first foray into the field of research working with the important zoonotic pathogen Toxoplasma gondii.I then gained a scholarship to work for two years as a laboratory assistant in the Immunology and Parasitology departments of the University of Yucatan in Mexico.Back in the UK I then completed my PhD in the immuno- pathogenesis of African Swine Fever Virus ASFV at the Institute for Animal HealthPirbright.During my PhD I carried out ground- breaking research identifying for the first time that ASFV-infected cells actually commit suicide undergo apoptosis and that certain types of immune cells CD8 cytotoxic T cells play a critical role in the hosts immune response to the virus.Both these findings played a leading role in understanding how and why ASFV causes such fatal clinical signs and helped the scientific community to target their approaches to vaccine develop- ment. Having completed my PhD I successfully secured two consecutive highly competitive Wellcome Trust Personal Fellow- ships which enabled me to make a name for myself in the Theileria research arena. The first of these fellowships was a four-year Advanced Training Fellowship which was awarded by the Tropical Interest Group of the Wellcome Trust during which time I investigated molecular aspects of the immunobiology of the bovine haemoparasite Theileria annulata.This fellowship resulted in several publications in which I used differential RNA display and proteomic technologies to identify genes that were involved in the life cycle stages of this important veterinary parasite. I was then awarded a personal Tropical Research Fellowship by the Tropical Interest Group of the Wellcome Trust to work in collabo- ration with the University of Glasgow and the University of Makerere in Uganda.I took full advantage of the rare opportunity to contribute to research in Uganda where I personally equipped and set up my own molecular research lab and then used this lab to investigate the molecular epidemiology and population genet- ics of Theileria parva.During this three-year fellowship I published a total of 12 papers eight first author which made a significant contribution to the understanding of the population structure of this important parasitewhich had very important implications for vaccine development. I returned from Uganda to the world famous Pirbright labora- tory in the UK where I spent the next eight years carrying out research on various exotic veterinary viruses. During this period I was head of the World Organisation for Animal Health OIE European Community and UK national reference lab for Bluetongue BThead of the OIE and UK national reference lab for African Horse Sickness AHS and African Swine Fever ASF and head of the OIE FAO world and UK national reference lab for Rinderpest and Peste de Petit Ruminants PPR. I was OIE designated disease expert for African Swine fever Bluetongue and African Horse Sickness from 2005-2012. During this period I contributed significantly to the control and eventual eradication of the first ever outbreak of BT in Northern Europe as well as the UK was laboratory operations manager during the outbreak of Foot and Mouth Diseases virus FMDV in the UK in 2007 and as head of the World Reference Laboratory for Rinderpest played a significant role in the final stages leading up to the global eradica- tion of Rinderpest in 2011.Research highlights during this period at IAH-Pirbright included the discovery that the BTV serotype that reached Northern Europe and the UK in 20067 was being transmitted both orally and transplacentally making it a unique and extremely dangerous strain of the virus. My research work investigating the efficiency and longevity of the immune response to BTV vaccination in sheep and cattle as well as the extent of colostral transfer of antibodies in calves and lambs and the levels of vaccine interference due to colostral antibodies in young animals optimised the use of the newly produced vaccine to BTV serotype 8 and contributed significantly to the successful control and eradication of the virus from Northern Europe. My research group also identified two new serotypes of BTV one of which BTV-26 was identified as being the first BTV to be transmitted from animal to animal by direct contact as opposed to via the bite of an infected Culicoides midge. This was the first report of any BTV strain being transmitted through direct contact and is a highly significant and potentially worrying finding considering the known potential of co-circulating BTV strains to undergo reassortment in the field. During this period at IAH- Pirbright I published widely in many areas including African Swine Fever Virus vaccine developmentAfrican horse sickness epidemi- ology sheepox goatpox and lumpy skin disease transmission MEDICAL SCIENCES Professor in Veterinary Virology School of Veterinary Medicine Tel 868 645 3232 ext. 4220 work 868 725 4263 mobile Fax 868 645 7428 E-mail PROF. CHRIS OURA